Adult Dosing .
Dosage forms: INJ
age-related macular degeneration, neovascular
- [2 mg intravitreally q8wk]
- Start: 2 mg intravitreally q4wk x12wk
macular edema, retinal vein occlusion-assoc.
- [2 mg intravitreally q4wk]
- [no adjustment]
- HD: not defined
- [not defined]
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.
- hypersens. to drug/class/compon.
- ocular or periocular infection
- active intraocular inflammation
Drug Interactions .
No significant interactions known or found for this drug. Caution always advised with multiple medications.
Adverse Reactions .
- retinal detachment
- IOP incr.
- hypersensitivity rxn
- conjunctival hemorrhage
- ocular pain
- vitreous detachment
- vitreous floaters
- IOP incr.
- conjunctival hyperemia
- corneal erosion
- retinal pigment epithelium detachment
- injection site pain
- foreign body sensation
- lacrimation incr.
- blurred vision
- retinal pigment epithelium tear
Lactation: Safety Unknown
IOP; optic nerve head perfusion
Metabolism: unknown; CYP450: unknown
Excretion: unknown; Half-life: 5-6 days (IV route)
Subclass: Other Ophthalmics
Mechanism of Action
binds and inhibits vascular endothelial growth factor A and placental growth factor, decreasing neovascularization and vascular permeability
Approximate Retail Price
This information is currently not available for this drug.
Join Now to View Patient Handouts!
Create a FREE Epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.
Current Members: Sign In.